Coya Therapeutics Inc (COYA)

$4.55 +0.13 (2.94%)
Market Cap 103.68M
Revenue (ttm) 7.95M
Net Income (ttm) -21.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -267.04%
Debt to Equity Ratio 0.00
Volume 83,900
Avg Vol 162,120
Day's Range N/A - N/A
Shares Out 23.46M
Stochastic %K 3%
Beta 0.62
Analysts Strong Sell
Price Target $15.19

Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 587 8170
Address:
5850 San Felipe St., Suite 500, Houston, United States
zampy
zampy Jun. 8 at 10:18 PM
$COYA A catalyst that is ignored...Dr Reddy's q3 to q4 FDA phase 3 outcome using Abatacept fir R.A. Helps COYA in many ways.... Big plus....
0 · Reply
Jwa68
Jwa68 Jun. 8 at 7:52 PM
$COYA And they recently added Mark Pavao who was a senior leader at BMS commercial to their Board. Reddy's better make it's move or they may get left at the altar...
1 · Reply
Jwa68
Jwa68 Jun. 8 at 7:09 PM
$COYA Regarding BMY, you know both Arun and Fred came from there, being former executives. Also BMY is the only other company that has the second half the combo that Reddy's is now supplying. I keep saying Reddy's strikes soon or they run the risk of getting into a bidding contest they simply cannot win.
0 · Reply
zampy
zampy Jun. 8 at 6:14 PM
$COYA My thoughts...May be right and may not be.... Before full enrollment I believe we our bought out.......$12 to $18 plus CVR'S. If RDY Snoozes priced out...By BMY.... M&A KICKING IN HIGH GEAR NOW....So between now and November that is what I believe before the data card.
0 · Reply
VINCE_CARTER
VINCE_CARTER Jun. 8 at 5:14 PM
$COYA $
0 · Reply
Robby83
Robby83 Jun. 8 at 4:32 PM
$COYA peppered in a few buys. Prepared to add more if we hit $4. I'm hopeful this channels sideways (worst case) in a range until a catalyst presents itself.
1 · Reply
zampy
zampy Jun. 8 at 3:44 PM
$COYA The Toferesen precedent.. Back in 2021 Biogen's Toferesen failed on their PRIMARY ENDPOINT...their drug did ZERO for the ALSFRS-R scores vs the placebo...an epic failure... However their secondary endpoint nfl saved the day..it only dropped 3.5% that day...they fought for nfl 15 months and the FDA because of their NFL biomarker voted unamiously 18 month later to approve Tofersen. We have the yriple threat Nfl..Hne and Lbp....Conviction very high! .
0 · Reply
zampy
zampy Jun. 8 at 2:15 PM
$COYA All about safety..tolerability..and now ENROLLMENT... There is no question we will be full enrollment 2nd half ....
0 · Reply
zampy
zampy Jun. 8 at 1:53 PM
$COYA "TRANSFORMATIONAL"
0 · Reply
DARKP00L
DARKP00L Jun. 8 at 1:28 PM
$COYA 08:06 on Jun. 08 2026 Coya Therapeutics Initiates Blinded Extension Phase Of Its ALSTARS Trial; Patients Who Complete The 24-Week Placebo-Controlled, Double-Blind Phase Enter The Blinded Extension Phase Of The Study #tradeideas
0 · Reply
Latest News on COYA
Coya Therapeutics initiates first cohort of patients in ALSTARS trial

2026-06-08T12:27:28.000Z - 13 hours ago

Coya Therapeutics initiates first cohort of patients in ALSTARS trial

Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase

Jun 8, 2026, 8:00 AM EDT - 13 hours ago

Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase

Coya Therapeutics initiated with a Buy at Roth Capital

2026-06-05T08:20:06.000Z - 3 days ago

Coya Therapeutics initiated with a Buy at Roth Capital

Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit

May 27, 2026, 8:00 AM EDT - 12 days ago

Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit

Coya Therapeutics Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 26 days ago

Coya Therapeutics Proxy statement: Proxy filing

Coya Therapeutics Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 26 days ago

Coya Therapeutics Proxy statement: Proxy filing

Coya Therapeutics granted FDA Fast Track Designation for COYA 302

2026-05-12T11:54:30.000Z - 27 days ago

Coya Therapeutics granted FDA Fast Track Designation for COYA 302

Coya Therapeutics reports Q1 EPS (32c), consensus (39c)

2026-05-12T11:49:47.000Z - 27 days ago

Coya Therapeutics reports Q1 EPS (32c), consensus (39c)

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 12, 2026, 7:35 AM EDT - 27 days ago

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

May 12, 2026, 7:30 AM EDT - 27 days ago

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:30 AM EDT - 27 days ago

Coya Therapeutics Earnings release: Q1 2026

Coya Therapeutics Quarterly report: Q1 2026

May 12, 2026, 7:30 AM EDT - 27 days ago

Coya Therapeutics Quarterly report: Q1 2026

Coya Therapeutics Slides: Investor presentation

May 11, 2026, 2:00 AM EDT - 4 weeks ago

Coya Therapeutics Slides: Investor presentation

Coya Therapeutics Slides: Corporate presentation

May 1, 2026, 7:00 AM EDT - 5 weeks ago

Coya Therapeutics Slides: Corporate presentation

Coya Therapeutics announces publication of research on COYA 302

2026-04-09T12:26:37.000Z - 2 months ago

Coya Therapeutics announces publication of research on COYA 302

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Apr 9, 2026, 8:00 AM EDT - 2 months ago

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Coya Therapeutics Executive Chairman Howard Berman steps down

2026-04-02T12:17:50.000Z - 2 months ago

Coya Therapeutics Executive Chairman Howard Berman steps down

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Coya Therapeutics Slides: Investor presentation

Apr 2, 2026, 7:00 AM EDT - 2 months ago

Coya Therapeutics Slides: Investor presentation

Coya publishes study showing reduction in regulatory T cell function in FTD

2026-03-18T12:38:33.000Z - 2 months ago

Coya publishes study showing reduction in regulatory T cell function in FTD

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Mar 18, 2026, 8:00 AM EDT - 2 months ago

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Coya Therapeutics Annual report: Q4 2025

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Annual report: Q4 2025

Coya Therapeutics Earnings release: Q4 2025

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Earnings release: Q4 2025

Coya Therapeutics Registration statement: Registration Filing

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Registration statement: Registration Filing

Coya Therapeutics Transcript: Status update

Feb 17, 2026, 3:00 PM EST - 3 months ago

Coya Therapeutics Transcript: Status update

Coya Therapeutics Slides: Status update

Feb 17, 2026, 3:00 PM EST - 3 months ago

Coya Therapeutics Slides: Status update

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Feb 10, 2026, 8:00 AM EST - 4 months ago

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Coya Therapeutics to sell 2.522M shares at $4.40 in private placement

2026-01-30T13:15:29.000Z - 4 months ago

Coya Therapeutics to sell 2.522M shares at $4.40 in private placement

RDY

Coya Therapeutics Announces $11.1 Million Private Placement

Jan 30, 2026, 8:00 AM EST - 4 months ago

Coya Therapeutics Announces $11.1 Million Private Placement

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Jan 20, 2026, 8:00 AM EST - 4 months ago

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Jan 8, 2026, 8:00 AM EST - 5 months ago

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Coya Therapeutics announces FDA acceptance of COYA 302 IND application

2026-01-05T13:05:21.000Z - 5 months ago

Coya Therapeutics announces FDA acceptance of COYA 302 IND application

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

Jan 5, 2026, 8:00 AM EST - 5 months ago

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

Coya announces Health Canada acceptance of COYA 302 clinical trial application

2025-12-23T13:11:52.000Z - 5 months ago

Coya announces Health Canada acceptance of COYA 302 clinical trial application

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Dec 23, 2025, 8:00 AM EST - 5 months ago

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics commences dosing in ALSTARS trial

2025-12-09T13:11:58.000Z - 6 months ago

Coya Therapeutics commences dosing in ALSTARS trial

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

Dec 9, 2025, 8:00 AM EST - 6 months ago

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

Coya Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:45 AM EST - 6 months ago

Coya Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Coya Therapeutics Slides: Investor Presentation

Nov 30, 2025, 6:00 PM EST - 6 months ago

Coya Therapeutics Slides: Investor Presentation

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

Nov 25, 2025, 8:00 AM EST - 6 months ago

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

Coya Therapeutics reports Q3 EPS (13c), consensus (30c)

2025-11-12T13:20:43.000Z - 7 months ago

Coya Therapeutics reports Q3 EPS (13c), consensus (30c)

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Nov 12, 2025, 8:00 AM EST - 7 months ago

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 7 months ago

Coya Therapeutics Quarterly report: Q3 2025

Coya Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 7 months ago

Coya Therapeutics Earnings release: Q3 2025

Coya Therapeutics price target raised to $17 from $16 at Lake Street

2025-11-05T13:50:45.000Z - 7 months ago

Coya Therapeutics price target raised to $17 from $16 at Lake Street

Coya Therapeutics announces results from COYA 303 in vivo animal study

2025-11-04T14:06:05.000Z - 7 months ago

Coya Therapeutics announces results from COYA 303 in vivo animal study

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Nov 4, 2025, 8:00 AM EST - 7 months ago

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Oct 27, 2025, 4:01 PM EDT - 8 months ago

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Coya Therapeutics 3.64M Spot Secondary priced at $5.50

2025-10-24T10:35:20.000Z - 8 months ago

Coya Therapeutics 3.64M Spot Secondary priced at $5.50

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Oct 24, 2025, 6:30 AM EDT - 8 months ago

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Coya Therapeutics announces common stock offering, no amount given

2025-10-23T20:35:37.000Z - 8 months ago

Coya Therapeutics announces common stock offering, no amount given

Coya Therapeutics Announces Proposed Public Offering of Common Stock

Oct 23, 2025, 4:31 PM EDT - 8 months ago

Coya Therapeutics Announces Proposed Public Offering of Common Stock

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

Oct 7, 2025, 8:00 AM EDT - 8 months ago

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

Coya Therapeutics completes enrollment in IL-2 and CTLA4-Ig study

2025-09-29T12:10:10.000Z - 9 months ago

Coya Therapeutics completes enrollment in IL-2 and CTLA4-Ig study

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics launches ALSTARS Trial to study efficacy of COYA 302

2025-09-22T12:15:58.000Z - 9 months ago

Coya Therapeutics launches ALSTARS Trial to study efficacy of COYA 302

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Sep 22, 2025, 8:00 AM EDT - 9 months ago

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Coya Therapeutics’ COYA 303 shows anti-inflammatory effect in animal study

2025-09-16T12:05:25.000Z - 9 months ago

Coya Therapeutics’ COYA 303 shows anti-inflammatory effect in animal study

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Sep 16, 2025, 8:00 AM EDT - 9 months ago

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Coya Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 10:00 AM EDT - 9 months ago

Coya Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

Sep 4, 2025, 8:00 AM EDT - 9 months ago

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Sep 3, 2025, 11:50 AM EDT - 9 months ago

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Sep 3, 2025, 8:34 AM EDT - 9 months ago

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Aug 25, 2025, 8:00 AM EDT - 10 months ago

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Coya Therapeutics Earnings release: Q2 2025

Coya Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Coya Therapeutics Quarterly report: Q2 2025

Coya Therapeutics Registration statement: Registration Filing

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Coya Therapeutics Registration statement: Registration Filing

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Jul 24, 2025, 8:15 AM EDT - 11 months ago

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Jul 22, 2025, 8:15 AM EDT - 11 months ago

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Coya Therapeutics Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2025

Jun 24, 2025, 10:30 AM EDT - 1 year ago

Coya Therapeutics Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2025

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Jun 18, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

Coya Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 12:30 PM EDT - 1 year ago

Coya Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 16, 2025, 10:53 AM EDT - 1 year ago

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Coya Therapeutics Proxy statement: Proxy Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Proxy statement: Proxy Filing

Coya Therapeutics Proxy statement: Proxy Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Proxy statement: Proxy Filing

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

May 13, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Quarterly report: Q1 2025

Coya Therapeutics Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Earnings release: Q1 2025

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

May 8, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

May 8, 2025, 5:00 AM EDT - 1 year ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

REPL

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Apr 24, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics Transcript: Planet MicroCap Showcase: VEGAS 2025

Apr 23, 2025, 2:00 PM EDT - 1 year ago

Coya Therapeutics Transcript: Planet MicroCap Showcase: VEGAS 2025

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Apr 21, 2025, 9:51 AM EDT - 1 year ago

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Apr 1, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Mar 26, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Mar 18, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Coya Therapeutics Annual report: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Annual report: Q4 2024

Coya Therapeutics Earnings release: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Earnings release: Q4 2024

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Feb 25, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Coya Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 10:00 AM EST - 1 year ago

Coya Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Feb 6, 2025, 8:00 AM EST - 1 year ago

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Jan 21, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Dec 18, 2024, 8:15 AM EST - 1 year ago

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Coya Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 12:55 PM EST - 1 year ago

Coya Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Nov 25, 2024, 8:15 AM EST - 1 year ago

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Coya Therapeutics Registration statement: Registration Filing

Nov 20, 2024, 7:00 AM EST - 1 year ago

Coya Therapeutics Registration statement: Registration Filing

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Nov 6, 2024, 8:00 AM EST - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Coya Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

Coya Therapeutics Quarterly report: Q3 2024

Coya Therapeutics Earnings release: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

Coya Therapeutics Earnings release: Q3 2024

zampy
zampy Jun. 8 at 10:18 PM
$COYA A catalyst that is ignored...Dr Reddy's q3 to q4 FDA phase 3 outcome using Abatacept fir R.A. Helps COYA in many ways.... Big plus....
0 · Reply
Jwa68
Jwa68 Jun. 8 at 7:52 PM
$COYA And they recently added Mark Pavao who was a senior leader at BMS commercial to their Board. Reddy's better make it's move or they may get left at the altar...
1 · Reply
Jwa68
Jwa68 Jun. 8 at 7:09 PM
$COYA Regarding BMY, you know both Arun and Fred came from there, being former executives. Also BMY is the only other company that has the second half the combo that Reddy's is now supplying. I keep saying Reddy's strikes soon or they run the risk of getting into a bidding contest they simply cannot win.
0 · Reply
zampy
zampy Jun. 8 at 6:14 PM
$COYA My thoughts...May be right and may not be.... Before full enrollment I believe we our bought out.......$12 to $18 plus CVR'S. If RDY Snoozes priced out...By BMY.... M&A KICKING IN HIGH GEAR NOW....So between now and November that is what I believe before the data card.
0 · Reply
VINCE_CARTER
VINCE_CARTER Jun. 8 at 5:14 PM
$COYA $
0 · Reply
Robby83
Robby83 Jun. 8 at 4:32 PM
$COYA peppered in a few buys. Prepared to add more if we hit $4. I'm hopeful this channels sideways (worst case) in a range until a catalyst presents itself.
1 · Reply
zampy
zampy Jun. 8 at 3:44 PM
$COYA The Toferesen precedent.. Back in 2021 Biogen's Toferesen failed on their PRIMARY ENDPOINT...their drug did ZERO for the ALSFRS-R scores vs the placebo...an epic failure... However their secondary endpoint nfl saved the day..it only dropped 3.5% that day...they fought for nfl 15 months and the FDA because of their NFL biomarker voted unamiously 18 month later to approve Tofersen. We have the yriple threat Nfl..Hne and Lbp....Conviction very high! .
0 · Reply
zampy
zampy Jun. 8 at 2:15 PM
$COYA All about safety..tolerability..and now ENROLLMENT... There is no question we will be full enrollment 2nd half ....
0 · Reply
zampy
zampy Jun. 8 at 1:53 PM
$COYA "TRANSFORMATIONAL"
0 · Reply
DARKP00L
DARKP00L Jun. 8 at 1:28 PM
$COYA 08:06 on Jun. 08 2026 Coya Therapeutics Initiates Blinded Extension Phase Of Its ALSTARS Trial; Patients Who Complete The 24-Week Placebo-Controlled, Double-Blind Phase Enter The Blinded Extension Phase Of The Study #tradeideas
0 · Reply
Jwa68
Jwa68 Jun. 8 at 1:18 PM
$COYA Just speculating, but this seems like great news. Can only mean doctors and patients must see value in staying on in study and that there are no safety issues. If they felt it was not working they would likely simply drop out. I assume this an important milestone for Dr. Reddy's who clearly knows the study is going well. $XBI
0 · Reply
zampy
zampy Jun. 8 at 1:10 PM
$COYA The clinical momentum is ahead of schedule. We dudnt employ the infracture until late Feb and in March we went to the FDA on Blood pressure meds and were granted an amendment. The final 60 patients enrolled will be very expedious in nature. Wirh the infracture rolling and less people being rejected because on blood pressure meds ( used to be every 19 patients 4 rejected) we are on hyperbolic speed relative to enrollment. Retail only moves on top line or shiny new objects Smart institutional investors will now know that the safety is intact. Today " I consider retail investors the dumbest people on the face of the earth."
1 · Reply
Jwa68
Jwa68 Jun. 8 at 12:44 PM
$COYA Great news continues...Reddy's makes their move soon in my mind. If notl, they may lose it to BMY...
0 · Reply
microcapspeculator
microcapspeculator Jun. 8 at 12:41 PM
$COYA Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase Jun 08, 2026 Patients with ALS who have completed the 24-week, double-blind, placebo-controlled Phase of the ALSTARS Trial, have entered the 24-week blinded extension period, during which all participants receive COYA 302
0 · Reply
john_Ennis
john_Ennis Jun. 8 at 12:01 PM
$COYA New day and a new week. Lets hope some Roths mates take their advice and start buying in big time.
1 · Reply
kosgolf2
kosgolf2 Jun. 7 at 10:19 PM
$COYA https://youtube.com/shorts/cIf4c1m88fs?si=CR36KZ_hEXoherBa
0 · Reply
zampy
zampy Jun. 7 at 3:54 PM
$COYA FOR CLARITY The readout will take place in Q1 of 2027 for 60 patients. 20 low dose 20 high dose and 20 on placebo. Read what the company has provided. The 2nd wave that will be blinded active will be 30 patients on low dose...and 30 on high dose. Hope this clears things up.
0 · Reply
zampy
zampy Jun. 7 at 2:54 PM
$COYA THE STRATIFICATION LOW..MEDIUM .AND HIGH...Again Dr APPEL....No one else doing this in their studies. Air tight.... common denominator DR STANLEY APPEL...Enormous RESPECT amongst the FDA
0 · Reply
zampy
zampy Jun. 7 at 2:24 PM
$COYA DR STANLEY APPEL EFFECT COYA approached the FDA on blood pressure meds being less restrictive in March.... April 9th Longitudal study of 100 patients...May 12th fast track. WHY DR STANLEY APPEL Opened 1st climic for ALS in 1982 ..LIVING LEGEND....BABE RUTH!!! WE ARE THE ONLY COMPANY IN THE UNIVERSE WITH THE TRIPLE PLAY: NFL HNE AND LBP HNE AND LBP predict survivability!!!!! THE FDA IS LISTENING!!!!
0 · Reply
zampy
zampy Jun. 6 at 8:10 PM
$COYA MON $4.91 CLOSE TUES $4.73 Wed $4.64 Thurs $4.87 Friday $4.42 Total volume 1.21m shares average 242k ...ave price $4.72 Last 100 k on Friday brought average down a lot... DONT LET 100K SHARES OF THE 1.21M FOR WEEK take you down....BS
0 · Reply
zampy
zampy Jun. 6 at 7:45 PM
$COYA Dec 9th we started the Enrollment on 3 arm study.....I believe we should be at half way point mid July..... My speculation is the complete enrollment will be done in November 1w0 people. May god bless the people on this study...We as shareholders are doing a good thing for humanity... Im cautiously optimistic.
2 · Reply
zampy
zampy Jun. 6 at 3:56 PM
$COYA A tale of the tape.. 1ST 100K AVE VWAP $4.93 2nd 34k AVE VWAP $4.71 3RD 100K AVE VWAP $4.46 AVERAGE VWAP $4.67.... So 1st 134k ave vwap was $4.82 Which is palatable....ONLY 100K SHOOK IT OUT IN FINAL HOUR....REALITY..NOT SO BAD...
0 · Reply